Pristimerin drives ROS-dependent apoptosis in cutaneous T-cell lymphoma via inhibition of the AKT-SKP2 axis
A natural compound shows promise in killing cutaneous lymphoma cells, and combining it with existing drugs suggests a potential new treatment path.
This study demonstrated that pristimerin kills cutaneous T-cell lymphoma cells through ROS-dependent, mitochondria-mediated apoptosis by inhibiting the AKT-SKP2 axis. Combination with bortezomib showed synergistic anti-CTCL activity, suggesting a potential therapeutic strategy for this underserved lymphoma subtype.
What the study was
- Study design
- Preclinical in vitro
- Population
- CTCL cell lines (H9, HH)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Toxicology and Applied Pharmacology
Why it surfaced
Novel compound targeting CTCL (rare lymphoma with limited options), but in vitro only. Capped at 5 for preclinical.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.